E
77.92
-0.28 (-0.36%)
前收盘价格 | 78.20 |
收盘价格 | 77.49 |
成交量 | 1,693,543 |
平均成交量 (3个月) | 4,890,374 |
市值 | 45,707,870,208 |
市盈率 (P/E TTM) | 32.20 |
预期市盈率 (P/E Forward) | 31.45 |
价格/销量 (P/S) | 8.28 |
股市价格/股市净资产 (P/B) | 4.45 |
52周波幅 | |
利润日期 | 22 Jul 2025 - 28 Jul 2025 |
营业毛利率 | 75.71% |
营业利益率 (TTM) | 29.01% |
稀释每股收益 (EPS TTM) | 2.42 |
季度收入增长率 (YOY) | 6.20% |
季度盈利增长率 (YOY) | 1.70% |
总债务/股东权益 (D/E MRQ) | 6.86% |
流动比率 (MRQ) | 4.45 |
营业现金流 (OCF TTM) | 876.20 M |
杠杆自由现金流 (LFCF TTM) | 1.45 B |
资产报酬率 (ROA TTM) | 8.42% |
股东权益报酬率 (ROE TTM) | 16.51% |
市场趋势
短期 | 中期 | ||
行业 | Medical Devices (US) | 看跌 | 混合的 |
Medical Devices (全球的) | 看跌 | 混合的 | |
股票 | Edwards Lifesciences Corporatio | 看涨 | 看涨 |
AIStockmoo 评分
-0.3
分析师共识 | -1.5 |
内部交易活动 | NA |
价格波动 | 1.0 |
技术平均移动指标 | -2.5 |
技术振荡指标 | 2.0 |
平均 | -0.25 |
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
部门 | Healthcare |
行业 | Medical Devices |
投资方式 | Mid Growth |
内部持股比例 | 0.91% |
机构持股比例 | 89.29% |
52周波幅 | ||
目标价格波幅 | ||
高 | 95.00 (Citigroup, 21.92%) | 购买 |
中 | 77.00 (-1.18%) | |
低 | 75.00 (Canaccord Genuity, -3.75%) | 保留 |
75.00 (Baird, -3.75%) | 保留 | |
平均值 | 81.00 (3.95%) | |
总计 | 2 购买, 3 保留 | |
平均价格@调整类型 | 75.65 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
Evercore ISI Group | 08 Jul 2025 | 77.00 (-1.18%) | 保留 | 76.79 |
Citigroup | 22 May 2025 | 95.00 (21.92%) | 购买 | 74.79 |
Piper Sandler | 13 May 2025 | 83.00 (6.52%) | 购买 | 75.50 |
24 Apr 2025 | 80.00 (2.67%) | 购买 | 75.13 | |
Canaccord Genuity | 25 Apr 2025 | 75.00 (-3.75%) | 保留 | 76.04 |
Baird | 24 Apr 2025 | 75.00 (-3.75%) | 保留 | 75.13 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合